After participating
in this activity, participants should be able to:
Outline the potential mechanisms leading to increased morbidity/mortality
from IDH.
Describe the physiological events occurring within major functional
systems (cardiovascular, neurological, hormonal) during hemodialysis
that can lead to IDH.
Identify the different treatments for maintaining BP during dialysis,
and the rationale for each.
Recognize and select the components of the dialysis prescription
which can be modified to decrease the risk for IDH.
Discuss
the pros and cons of various pharmacological treatments for IDH.
 |
John
T. Daugirdas, MD
Professor of Medicine
University of Illinois at Chicago School of Medicine
Andrew
J. King, MD
Division of Nephrology
Scripps Clinic
Mark
A. Perazella, MD, MS
Associate Professor of Medicine
Director of Acute Dialysis Services
Yale University School of Medicine
Martin
J. Schreiber, Jr, MD
Department of Nephrology and Hypertension
The Cleveland Clinic Foundation
Richard
A. Sherman, MD
Director of ESRD Services
University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School
|
|
 |
This
activity has been planned and implemented in accordance
with the Essential Areas and Policies of the Accreditation
Council for Continuing Medical Education (ACCME)
through the joint sponsorship of Professional
Postgraduate Services® (PPS) and Advanced HealthMarket
Strategies™, divisions of Physicians World/Thomson
Healthcare.
PPS
is accredited by the ACCME to provide continuing
medical education for physicians.
PPS
designates this educational activity for a maximum
of 2 hours in category 1 credit toward the AMA Physician's
Recognition Award. Each physician should claim only
those hours he/she spent in the educational activity. |
Post-test and evaluation form are at
this link, but you must listen to
all four talks from this symposium
prior to completing the test. |
|
|
|
|
Intradialytic
hypotension (IDH) is a distinct syndrome affecting as many as
20% to 50% of patients undergoing hemodialysis. Patients developing
IDH require a significantly higher acuity of care. In addition
to causing nausea, vomiting, cramping, dizziness and fatigue,
IDH may also be associated with cerebrovascular insufficiency,
cardiac instability, and thrombosis. To lower these risks, it
is critical to fully understand the physiology of IDH and its
treatment.
This
program is designed for clinicians who are involved in the care
of hemodialysis patients who experience IDH.
|
FACULTY
DISCLOSURE STATEMENTS : |
Professional
Postgraduate Services® (PPS) and Advanced HealthMarket Strategies™,
divisions of Physicians World/Thomson Healthcare has a conflict
of interest policy that requires course faculty to disclose
any real or apparent commercial financial affiliations related
to the content of their presentations/materials. It is not assumed
that these financial interests or affiliations will have an
adverse impact on faculty presentations; they are simply noted
here to fully inform participants.
 Dr. Schreiber
has indicated a financial interest or affiliation as follows:
Honoraria: Baxter Healthcare Corporation.
Dr. Daugirdas
has indicated no significant financial interests or affiliations.
Dr. Sherman
has indicated no significant financial interests or affiliations.
Dr. Perazella
has indicated a financial interest or affiliation as noted:
Consultant/Speaker: Shire US, Inc.
Dr. King
has indicated no significant financial interests or affiliations.
|
DISCLOSURE OF UNLABELED USE ASN/HDCN (if applicable): |
This
educational activity contains discussion of published and/or
investigational uses of agents that are not indicated by FDA.
Professional Postgraduate Services® (PPS) and Advanced HealthMarket
Strategies™, divisions of Physicians World/Thomson Healthcare,
ASN, HDCN do not recommend the use of any agent outside of the
labeled indications. Please refer to the official prescribing
information for each product for discussion of approved indications,
contraindications and warnings.
All
of the agents overviewed in this virtual symposium will be discussed
in the context of uses for which they have not been approved
by the FDA. |
|
